49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05048238 (ClinicalTrials.gov) | September 30, 2022 | 31/8/2021 | Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus | Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus (ALE11) | Systemic Lupus Erythematosus;Cutaneous Lupus | Drug: Tofacitinib | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Recruiting | 18 Years | 65 Years | All | 10 | Phase 1 | United States |
| 2 | NCT03288324 (ClinicalTrials.gov) | August 23, 2017 | 29/8/2017 | Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus | A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus | Cutaneous Lupus;Systemic Lupus Erythematosus | Drug: Tofacitinib | Children's Hospital Medical Center, Cincinnati | Pfizer | Completed | 18 Years | 45 Years | All | 13 | Phase 1/Phase 2 | United States |
| 3 | NCT03159936 (ClinicalTrials.gov) | April 3, 2017 | 2/5/2017 | Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) | Open Label Phase 2 Pilot Trial of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) | Discoid Lupus Erythematosus;Systemic Lupus Erythematosus | Biological: Tofacitinib citrate | Tufts Medical Center | Pfizer | Recruiting | 18 Years | 65 Years | All | 12 | Early Phase 1 | United States |
| 4 | NCT02535689 (ClinicalTrials.gov) | August 28, 2015 | 28/8/2015 | Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus | Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies | Systemic Lupus Erythematosus | Drug: Tofacitinib;Drug: Placebo | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | Completed | 18 Years | 100 Years | All | 34 | Phase 1 | United States |